The Council of Scientific and Industrial Research (CSIR) has developed indigenous technology to produce paracetamol, a widely used pain reliever and fever reducer. This innovation aims to reduce India's dependence on imported raw materials for paracetamol production, aligning with Prime Minister Narendra Modi's vision of Atmanirbhar Bharat (self-reliant India).
Karnataka-based Satya Deeptha Pharmaceuticals Ltd will utilize this breakthrough to produce affordable paracetamol domestically. This move is expected to make India self-reliant in paracetamol manufacturing and contribute to the country's pharmaceutical self-sufficiency.
Notably, India imports the key raw materials for paracetamol production from several countries. The primary sources include China, Germany, and France. This reliance on imports has been a significant factor in the development of indigenous technology by CSIR to produce paracetamol domestically.
India has made significant strides in developing indigenous drugs namely India’s 1st Indigenously developed Antibiotic- Nafithromycin to treat both atypical and typical drug-resistant bacteria.
Earlier, India has also conducted first successful trial of gene therapy for treating haemophilia, a blood disorder. The Modi government in India also led successful cultivation of lavender and other aromatic plants under the Aroma Mission initiative.
These advancements highlight India's growing capabilities in pharmaceuticals and other sectors. It's an exciting time for innovation in the country.
Advertisements